Next 10 |
Ginkgo Bioworks Completes Acquisition of Zymergen PR Newswire BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced t...
Summary Pursuing a horizontal platform strategy before the synthetic biology industry develops creates a risk of insufficient demand. Ginkgo’s ability to capture downstream value is promoted, but companies like Synlogic and Cronos have not inspired confidence so far. Th...
Gainers: Stabilis Solutions ( SLNG ) +12% . Cadiz ( CDZI ) +12% . DMC Global ( BOOM ) +10% . Denbury ( DEN ) +9% . HighPeak Energy ( HPK ) +9% . Losers: Amyris ( AMRS ) -15% . Eco Wave Power Global (publ) ( WAVE ) -14% ...
Blueprint Medicines ( BPMC ) -13% on reports to seek label expansion for systemic mastocytosis therapy after trial win . Artelo Biosciences ( ARTL ) -13% . Krispy Kreme ( DNUT ) -12% on Q2 earnings release . Forza X1 ( FRZA ) -12% . ...
Shares of Gingko Bioworks have lost over half their value so far in 2022. Successful acquisitions and joint ventures, such as with Bayer, could allow for additional customer capture and revenue acceleration. Gingko stands to benefit from current market environment as companies ree...
Gainers: American Resources ( AREC ) +12% . GasLog Partners ( GLOP ) +12% . Zymergen ( ZY ) +11% . NextDecade ( NEXT ) +9% . Danimer Scientific ( DNMR ) +9% . Losers: Save Foods ( SVFD ) -37% . Polished.com ( POL ) -33%...
Gainers: 5E Advanced Materials ( FEAM ) +16% . Zymergen ( ZY ) +13% . Polished.com ( POL ) +12% . Exterran ( EXTN ) +10% . Amplify Energy ( AMPY ) +10% . Losers: Pan American Silver ( PAAS ) -15% . Heliogen ( HLGN ) -11...
NEW YORK, NY / ACCESSWIRE / July 28, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hanger, Inc. (NYSE:HNGR)'s sale to...
An acquisition was probably the only viable option for Zymergen, but shareholders are likely to be disappointed by the price, given the company’s ambitions at the IPO. The deal makes sense for Ginkgo as it reduces competition and expands its capabilities at a minimal cost. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Zymergen (NASDAQ: ZY ) are moving higher on “Merger Monday,” with ZY stock up about 15% on the day. The move comes following news of Ginkgo Bioworks (NYSE: DNA ) acquiring the company. Bo...
News, Short Squeeze, Breakout and More Instantly...
Ginkgo Bioworks Completes Acquisition of Zymergen PR Newswire BOSTON and EMERYVILLE, Calif. , Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced t...